Product Description
Mechanisms of Action: Gene Therapy, MTM1
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Astellas Pharma
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Myopathies, Structural, Congenital|X-linked myotubular myopathy
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07876804 |
2957-CL-4001 | P2 |
Not yet recruiting |
X-linked myotubular myopathy|Myopathies, Structural, Congenital |
2032-07-31 |
6% |
2026-10-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|